The Importance of the DEIC/GEMIC/SBC 2021 Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis to Clinical Practice

The latest edition of Arquivos Brasileiros de Cardiologia has brought us the publication of the Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis by the DEIC/ GEMIC/SBC. This document was the result of the collaborative efforts of many experts in the area, exponents of cardiology in Brazil, but it also included other specialists, such as neurologists, hematologists and nuclear physicians. The need to bring together this group of collaborators reflects a fundamental aspect of amyloidosis, namely, a complex and multifaceted disease that affects multiple organs and requires the assistance of several specialties for comprehensive management. This was, in fact, a positive aspect of the document: its scope and multidisciplinary character. It is here appropriate to state the reasons that led the DEIC/GEMIC/SBC to produce this document, fulfilling the mission of producing documents that contribute to updating science and medical education, offering the signposts that are necessary to guide the practice of cardiology based on scientific evidence. The sense of urgency for this action was the clear perception of the recent and profound reformulation of concepts regarding cardiac amyloidosis (CA), including evidence that it is a more prevalent disease than previously imagined, the significant advance in imaging methods that has made non-invasive diagnosis possible, and the emergence of new specific treatments that can change the natural history of the disease (Figure 1).